Kos Fund Closes at $123M, ParcelBio Launches with $13M, Korsana Emerges with $175M

Three biotech and life sciences companies recently announced significant funding milestones. Korsana Biosciences emerged from stealth with $175 million in backing to develop therapies for neurodegenerative diseases, Kos Biotechnology Partners closed its inaugural life sciences fund at $123 million, and ParcelBio launched with $13 million in seed financing to advance next-generation mRNA medicines.

Korsana Biosciences, focused on reducing the burden of neurodegenerative diseases, secured initial financing expected to fund activities into 2028. The company was founded in 2024 with a $25 million seed investment from Fairmount and Venrock Healthcare Capital Partners. In September 2025, it closed a $150 million private Series A financing co-led by Wellington Management and TCGX, with participation from JP Morgan Life Sciences Private Capital, Janus Henderson Investors, Sanofi Ventures, Foresite Capital, and others. The funding is being used to develop potential best-in-class therapeutics, with an initial focus on Alzheimer’s disease. Key clinical milestones include potentially differentiating pharmacokinetics, CNS penetration, and safety data from healthy volunteers expected in mid-year 2027, and initial proof of concept data demonstrating amyloid plaque clearance in Alzheimer’s patients expected by the end of 2027.

Kos Biotechnology Partners announced the third closing of its inaugural global life sciences fund, bringing total capital commitments to $123 million (€106 million). Launched in December 2025, the fund has attracted support from institutional investors and family offices, including lead investor Hellenic Development Bank of Investments. The vehicle represents the first life sciences-focused investment fund established in Greece and the largest venture capital fund launch in the country’s history. It is also among the largest first-time life sciences venture capital fund launches in Europe. Kos invests across all stages of company development, from formation through Series C financings, and focuses on three primary sectors: biotechnology and novel therapeutics, pharmaceutical services, and technology-enabled healthcare platforms. The firm has already completed two investments: leading a financing round for tech-enabled pharmaceutical services company Epikast and making an investment in a San Francisco-based biotechnology company. Additional investments are expected later this year.

ParcelBio launched with $13 million in seed financing led by Breyer Capital, with participation from General Catalyst, Y Combinator, Metaplanet, SurgePoint Capital, ZAKA VC, and other investors. The financing will support development of ParcelBio’s proprietary APEXm™ (Amplified and Prolonged EXpression mRNA) platform and advance its pipeline, including its lead in vivo CAR-T program for autoimmune disease, as well as additional programs in oncology and encoded protein therapeutics. Preclinical data demonstrate that ParcelBio’s APEXm™ RNA drives significantly higher and more durable protein expression compared to a leading clinical mRNA design. The company will debut the APEXm™ platform and preclinical data in an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting on May 14, 2026.